New hope for pancreatic cancer? phase 3 trial pits novel combo against standard therapy
NCT ID NCT07238283
First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This Phase 3 trial tests whether a new combination of drugs (irinotecan liposome, oxaliplatin, 5-FU, and calcium folinate) works better than the current standard (nab-paclitaxel and gemcitabine) for people with metastatic pancreatic cancer that hasn't been treated yet. About 662 participants will be randomly assigned to one of the two treatments. The main goal is to see if the new combo helps people live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIRST-LINE TREATMENT OF METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.